In a new job - October 15, 2014
New CEO for Karolinska Development
Bruno Lucidi has been appointed permanent CEO of Karolinska Development. Bruno Lucidi has previously been founding CEO of Idenix and Chairman of Pharmasset. He has also held senior positions within Bristol-Myers Squibb, Johnson & Johnson and at GlaxoSmithKline. Since September 8, 2014, Bruno Lucidi is CEO of the Karolinska Development’s wholly owned subsidiary KDev Oncology as well […]
Science Award - October 15, 2014
Research award to microbiology professor
Researcher and professor Catharina Svanborg and the politician Barbro Westerholm have received Research! Sweden’s scientists award 2014. The independent foundation Research! Sweden has decided to award Catharina Svanborg for her groundbreaking research. Svanborg is professor of microbiology at Lund University and chief physician at Skåne University Hospital. “Catharina’s research has been of great importance for […]
Regulatory compliance - October 14, 2014
AstraZeneca sued for fraud
The pharmaceutical giant is being sued by the Texas Attorney General Greg Abbott. Abbott claims that AstraZeneca has been illegally marketing its antipsychotic Seroquel (quetiapine fumarate) for unapproved uses and paying kickbacks to physicians and state health officials. The Texas AG’s action builds on whistleblower suits that have been filed by two former AZN sales […]
New Market - October 14, 2014
Probi to launch Probi Digestis in Brazil
Probi has signed a distribution agreement with Laboratório Daudt, the oldest Brazilian pharmaceutical company with market presence since 130 years. Following registration, Lab. Daudt plans to launch Probi Digestis during 2015. Probi AB and Lab. Daudt have agreed to launch the probiotic supplement – Probi Mage – on the Brazilian market. “Key to success in such a […]
Drug Development Pharma - October 13, 2014
Orexo applies for expanded label of ZUBSOLV
The Uppsala-based company has submitted an application to the U.S. Food and Drug Administration for an expanded label of ZUBSOLV. Orexo hopes to include initiation of treatment for opioid dependence. The company now anticipates a potential approval of the expanded label during the third quarter 2015. “The FDA submission constitutes an important milestone for ZUBSOLV. Today we take […]
Acquisition - October 13, 2014
Meda launches rights issue to help pay for Rottapharm
As part of the financing of the acquisition of Rottapharm, Meda’s Board of Directors has resolved to launch a rights issue of approximately SEK 2.0 billion. On 31 July 2014, Meda announced entering into an agreement to acquire the Italian specialty pharma company Rottapharm S.p.A. Completion of the transaction was subject to certain conditions, including […]
